A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105): A Prospective, Multicenter Study
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
A observational or N/A phase clinical study on Portal Hypertension, this trial is ongoing. The trial is conducted by Hepatopancreatobiliary Surgery Institute of Gansu Province and has accumulated 5 data snapshots since 2023. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
5 versions recorded-
Oct 2025 — Present [monthly]
Unknown
Status: Not Yet Recruiting → Unknown
-
Sep 2024 — Oct 2025 [monthly]
Not Yet Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting
-
May 2023 — Jul 2024 [monthly]
Not Yet Recruiting
-
Oct 2021 — May 2023 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- LanZhou University
- Shulan (Hangzhou) Hospital
- The Third People's Hospital of Taiyuan
For direct contact, visit the study record on ClinicalTrials.gov .